Newomics
Omics solutions enhancing precision medicine with high sensitivity, throughput, and robust plug-and-play design.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
$7.9m | Series B | ||
| Total Funding | 000k | ||
Newomics specializes in providing advanced omics solutions tailored for precision medicine, focusing on high sensitivity and throughput. The company operates in the life sciences market, serving clients such as research institutions and pharmaceutical companies. Its core product, the UniESI ion source, is equipped with M3 emitters and MEA chips, enabling nano microflow LCMS applications. This technology significantly improves the analysis of small molecules, including lipids and glycans, by enhancing sensitivity and reducing in-source fragmentation. Newomics generates revenue through the sale of its proprietary instrumentation and consumables, catering to the growing demand for precise and efficient analytical tools in metabolomics and lipidomics. The business model is centered around product sales and customer support, ensuring robust performance and reliability for its users.
Keywords: precision medicine, omics solutions, high sensitivity, throughput, LCMS, metabolomics, lipidomics, UniESI, M3 emitters, life sciences.